• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
Shop

New Study Shows Candy-Flipping Can Reduce Bad Trips

Microdose NewsDesk by Microdose NewsDesk
September 7, 2023
in Science
Reading Time: 2 mins read
A A
candy flipping

A new study published in Nature shows that MDMA can reduce difficult experiences with other psychedelics.

“Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences” was published by researchers from Imperial College London and New York University’s Langone Center for Psychedelic Medicine.

The survey followed almost 700 people who’d used LSD or psilocybin, with 27 using MDMA in conjunction with the classic psychedelics. The results suggest that small doses of MDMA can potentially minimize the effects of a bad trip.

“Regarding positive experiences, co-use of low dose MDMA (but not medium–high dose MDMA) with psilocybin/LSD was associated with enhanced feelings of self-compassion, love, and gratitude relative to psilocybin/LSD alone.”

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Image1

Purchase Quick Lasix Online

 

Continue on your trip...

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

“Findings from this study suggest that co-use of low dose MDMA with psilocybin/LSD may buffer against negative or challenging experiences and enhance certain positive experiences. These findings may inform future clinical trial designs and provide early insights into recreational co-use of MDMA with psilocybin/LSD.”

Psychedelic experiences can bring up difficult emotions, and can cause anxiety in patients as they confront these challenging scenarios. Will MDMA be used to “buffer” against these rough patches? With therapists and drug developers looking to create the most efficient treatment models, this paper adds potentially useful data to optimize future therapy options.

Note: This study adds more context to another “candy-flipping” study published earlier this year by the Liechti team in Basel. This study was owned by MindMed, who also holds a patent for combining MDMA with LSD.

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Tags: LSDMDMA
Microdose NewsDesk

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Next Post
lab

Awakn Life Sciences Submits Clinical Trial Application for Phase 3 Trial

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.